CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 10 enrolled
Drug / intervention
d6-25-hydroxyvitamin D3drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03104855
NCT03104855Phase 1Completed
CompareCT.gov

Clearance of 25-hydroxyvitamin D in Cystic Fibrosis

University of Washington·interventional·Posted Apr 7, 2017·Updated Oct 12, 2023

In Brief

A Phase 1 clinical trial evaluating d6-25-hydroxyvitamin D3 for Cystic Fibrosis. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The goal of this study is to define 25(OH)D3 catabolism in CF patients using gold standard pharmacokinetics studies. Specifically, the investigators will evaluate the metabolic clearance of 25(OH)D3 among participants with CF and matched control subjects. The goal of this work is to provide the first comprehensive characterization of vitamin D metabolism in CF patients and promote novel hypotheses for subsequent studies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 7, 2017
Enrollment StartApr 3, 2017
Primary CompletionOct 9, 2018
Study CompletionSep 6, 2023
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 9.2 years ago

Interventions

d6-25-hydroxyvitamin D3drug

intravenous administration of stable isotope-labeled D6-25(OH)D3